Patents by Inventor Tracy Spalding

Tracy Spalding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY
    Publication number: 20090209525
    Abstract: A method developed to identify receptor modulators, involving providing a mutant receptor, wherein said mutant receptor has a mutation that alters the activity of said mutant receptor compared to a wild type receptor; contacting said mutant receptor with a candidate compound; and determining whether said candidate compound modulates the activity of said mutant receptor.
    Type: Application
    Filed: December 19, 2008
    Publication date: August 20, 2009
    Inventors: Tracy A Spalding, Mark R. Brann, Robert E. Davis, Ethan S. Burstein
  • Compounds with activity on muscarinic receptors
    Patent number: 7485651
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: February 3, 2009
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • G-PROTEIN COUPLED RECEPTORS HIGH-THROUGHPUT FUNCTIONAL ASSAY
    Publication number: 20080280303
    Abstract: Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conduction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
    Type: Application
    Filed: May 12, 2008
    Publication date: November 13, 2008
    Inventors: Ethan S. Burstein, Fabrice Piu, Jian-Nong Ma, Jacques Weissman, David M. Weiner, Audra L. Scully, Norman Nash, Tracy Spalding, Erika Currier
  • COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS
    Publication number: 20080108618
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • MUSCARINIC AGONISTS
    Publication number: 20070155795
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: February 16, 2007
    Publication date: July 5, 2007
    Applicant: ACADIA Pharmaceuticals Inc.
    Inventors: Carl-Magnus Andersson, Bo Lennart Friberg, Niels Skjaerbaek, Tracy Spalding, Allan Uldam
  • Muscarinic agonists
    Patent number: 7238713
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: July 3, 2007
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Carl-Magnus A. Anderson, Bo Lennart M. Friberg, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam
  • G-protein coupled receptors high-throughput functional assay
    Publication number: 20050123964
    Abstract: Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conjuction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
    Type: Application
    Filed: November 2, 2004
    Publication date: June 9, 2005
    Inventors: Ethan Burstein, Fabrice Piu, Jian-Nong Ma, Jacques Weissman, David Weiner, Audra Scully, Norman Nash, Tracy Spalding, Erika Currier
  • Muscarinic agonists
    Publication number: 20050113357
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: July 17, 2003
    Publication date: May 26, 2005
    Inventors: Carl-Magnus Anderson, Bo Friberg, Niels Skjaerbaek, Tracy Spalding, Allan Uldam
  • Muscarinic agonists
    Patent number: 6627645
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: September 30, 2003
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Carl-Magnus A. Andersson, Bo Lennart M. Friberg, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam
  • Compounds with activity on muscarinic receptors
    Publication number: 20030144285
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: January 7, 2003
    Publication date: July 31, 2003
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Compounds with activity on muscarinic receptors
    Patent number: 6528529
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 4, 2003
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Muscarinic agonists
    Publication number: 20020037886
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: April 27, 2001
    Publication date: March 28, 2002
    Inventors: Carl-Magnus A. Andersson, Bo Lennart M. Fribert, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam